Home » Archives by category » Publications (Page 4)

Patient Safety Paramount for Cutting Edge Medicines

Patient Safety Paramount for Cutting Edge Medicines

Huff Post: Gary Puckrein – Posted: 12/06/11 05:30 PM ET. Today’s advanced medicines, known as biologics, treat some of the most serious and costly medical conditions like cancer, diabetes, and kidney disease. Though it is impossible to make generic versions of these drugs, the 2010 Affordable Care Act has instructed the FDA to figure out […]

The Democratization of Health Care: The Independent Payment Advisory Board

Huffington Post: By Gary Puckrein – Posted: 03/ 4/2012 2:46 pm You probably missed this one, but this bit of legislation will have profound implications not only for your health, but the health of our economy. A provision of the Patient Protection and Affordable Care Act (PPACA) created a 15-member Independent Payment Advisory Board (IPAB), delegating […]

Issue Brief: Specialty Tiers: Unequal Treatment

Issue Brief 3: Specialty Tiers: Unequal Treatment by Gary A. Puckrein, PhD, and Gretchen C. Wartman Assigning drugs to specialty reimbursement tiers exerts different effects on patient care by design.  

Issue Brief: Low Consumption and Higher Medicare Cost: Consumption Clusters in a Medicare Fee-for-Service Population

Issue Brief 2: Low Consumption and Higher Medicare Cost: Consumption Clusters in a Medicare Fee-for-Service Population by Gary Puckrein, PhD; Sean D. Cleary, PhD, MPH; and Mira Shapiro, MS Analysis suggests that beneficiaries with chronic diseases who are low consumers of benefits tend to cost Medicare significantly more in the near term.

Issue Brief: Drug Prices and the Emerging Majority: Should Government Negotiate Drug Prices?

Issue Brief 1: Drug Prices and the Emerging Majority: Should Government Negotiate Drug Prices? (272 kb PDF) by Gary A. Puckrein, PhD; Randall W. Maxey, MD, PhD; Rene Rodriguez, MD; and Peter R. Deutsch, JD Virtually lost in the discussion about drug prices is any recognition that the methods used to contain drug prices could undermine the health of the emerging majority of the US population.

Origins and Strategies for Addressing Ethnic and Racial Disparities in Pharmaceutical Therapy

Origins and Strategies for Addressing Ethnic and Racial Disparities in Pharmaceutical Therapy: The Health-Care System, the Provider, and the Patient by Richard Levy, PhD; Robert C. Like, MD, MS; and Harry S. Shabsin, PhD   Landmark publication reveals disparities in pharmaceutical treatment for minority patients—a must read for those committed to eliminating health care disparities. This authoritative, comprehensive resource provides systematic documentation about the impact […]

Flow of Funds in U.S. Health Care

Flow of Funds in U.S. Health Care

Employer contributions to premiums for employee’s health insurance are paid in lieu of additional wages, which are received by the employee tax free under current law. Similarly, the employee’s premium contribution is collected through payroll deduction before these wages are taxed.  

Page 4 of 41234